Provided herein are methods for treating a patient suffering from cancer with an natural killer (NK) cell with a KIR-B haplotype and expresses a CD16 molecule, and a bispecific antibody which binds CD16 and CD30, along with methods of producing NK cell populations, and pharmaceutical compositions comprising the NK cells and bispecific antibodies.

The present invention provides cellular tags including an extracellular region, a transmembrane region, and an optional intracellular region. The extracellular region comprises an IL5 receptor alpha (IL5Ra) sequence linked to a transmembrane domain, and the recombinant polypeptide cannot function in signal transduction. The cellular tags can be operably linked to transgenes. The expression of the cellular tag allows identification, detection, selection, and ablation of cells expressing the transgene and the cellular tag. In some embodiments the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, and a polynucleotide coding for a cellular tag. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

Disclosed are receptor cytokine switches, immune cells containing them, and uses thereof for controllable adoptive cell therapy.

The current disclosure provides polypeptide constructs and cells comprising CDR3 regions of 9. 2 or both, that selectively bind a J-configuration of CD277 on a target cell. The disclosure also provides pharmaceutical compositions with the disclosed polypeptides or cells and methods of using these compositions in the treatment of cancer.